Investors
OMX Stockholm
( %)
HNSA SEK
Some content on this page is only available in English. All material required under applicable law, regulation or code is available in English and Swedish.
Calendar
Upcoming events
23Apr
Interim Report for January-March 2026
01Jun
Annual General Meeting 2026
16Jul
Interim Report for January-June 2026
Press releases
Our latest press releases
Hansa Biopharma publishes 2025 Annual and Sustainability Reports
Regulatory press release
26/03/2026
Hansa Biopharma announces a USD 30 million convertible note financing
Regulatory press release
20/03/2026
Hansa Biopharma presenting at Redeye Theme Event: Commercialization in Life Science
13/03/2026
Hansa Biopharma participating at DNB Carnegie Healthcare Conference 2026
10/03/2026
Hansa Biopharma in brief
Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life altering treatments for patients with rare immunological conditions.
